|
WO2020117740A1
|
|
Recombinant hiv env polypeptides and their uses
|
|
WO2020113199A1
|
|
Recombinant hiv env polypeptides and their use
|
|
WO2020086446A1
|
|
Anti-hiv antibodies
|
|
WO2020023827A1
|
|
Engineered antibodies to hiv env
|
|
EP3801601A1
|
|
Ferritin nanoparticle displaying an hiv trimer
|
|
US2019135872A1
|
|
N-glycan deleted HIV-1 envelope glycoprotein trimers
|
|
WO2019014405A1
|
|
Rapid elicitation of broadly neutralizing antibodies to hiv env
|
|
US2017266272A1
|
|
Transgenic Vero-CD4/CCR5 cell line
|
|
WO2017165674A1
|
|
Immunogenic trimers
|
|
US2017095551A1
|
|
Replication-competent VSV-HIV Env vaccines
|
|
WO2017007646A1
|
|
Hiv-1 clade c envelope glycoproteins
|
|
WO2016205704A2
|
|
Engineered outer domain (eod) of hiv gp120, mutants and use thereof
|
|
EP3072901A1
|
|
Soluble hiv-1 envelope glycoprotein trimers
|
|
EP3069730A2
|
|
Soluble hiv-1 envelope glycoprotein trimers
|
|
US2016201087A1
|
|
Neutralization-resistant CDV mutants and viral vectors
|
|
WO2016069518A2
|
|
Genetically stable replication competent sendai virus vector(s) containing and expressing optimized hiv genes
|
|
WO2016065252A2
|
|
Native trimeric env immunogen design
|
|
US2016033532A1
|
|
Mammalian protein co-recognition by broadly neutralizing antibodies as modified immunogens for re-elicitation
|
|
US2015361160A1
|
|
Broadly neutralizing antibody and uses thereof
|
|
EP2873423A2
|
|
Soluble hiv-1 envelope glycoprotein trimers
|
